中国医师进修杂志
中國醫師進脩雜誌
중국의사진수잡지
CHINESE JOURNAL OF POSTGRADUATES OF MEDICINE
2009年
33期
10-12
,共1页
舒芬太尼%甲状腺%镇痛
舒芬太尼%甲狀腺%鎮痛
서분태니%갑상선%진통
Sufentanil%Thyroid gland%Analgesia
目的 评价不同剂量舒芬太尼对甲状腺手术患者的镇静和镇痛效果.方法 择期行甲状腺手术的60例患者随机分为三组:A、B、C组,每组各20例,分别于手术开始切皮前10min缓慢静脉推注舒芬太尼0.1、0.2、0.3μg/kg,然后以0.1ug/(kg·h)速度持续输注.记录三组患者在手术切皮时(T1)、术中牵拉甲状腺时(T2)及缝皮时(T3)的平均动脉压(MAP)、心率(HR)、脉搏血氧饱和度(SpO2)、呼吸频率(RR)、镇静评分和镇痛评分,并进行比较.结果 B、C组T1、T2 Ramsay分级达Ⅳ级的例数(B组13、14例,C组14、15例)明显多于A组(7、10例)(P<0.05).但B组与C组比较差异无统计学意义(P>0.05 . B、C组视觉模拟评分(VAS)明显低于A组(P<0.05). A组T2 MAP、HR与T1、T3比较差异均有统计学意义(P<0.05);B和C组T1、T2、 HR与A组比较差异均有统计学意义(P<0.05);C组T2 SpO2:有所下降,但与A组和B组比较差异无统计学意义(P>0.05);C组T2RR与T1、T3比较差异均有统计学意义(P<0.05).结论 舒芬太尼可以安全有效地用于甲状腺手术中镇静和镇痛,以0.2 μg/(kg·h）的负荷剂量持续输注效果更佳.
目的 評價不同劑量舒芬太尼對甲狀腺手術患者的鎮靜和鎮痛效果.方法 擇期行甲狀腺手術的60例患者隨機分為三組:A、B、C組,每組各20例,分彆于手術開始切皮前10min緩慢靜脈推註舒芬太尼0.1、0.2、0.3μg/kg,然後以0.1ug/(kg·h)速度持續輸註.記錄三組患者在手術切皮時(T1)、術中牽拉甲狀腺時(T2)及縫皮時(T3)的平均動脈壓(MAP)、心率(HR)、脈搏血氧飽和度(SpO2)、呼吸頻率(RR)、鎮靜評分和鎮痛評分,併進行比較.結果 B、C組T1、T2 Ramsay分級達Ⅳ級的例數(B組13、14例,C組14、15例)明顯多于A組(7、10例)(P<0.05).但B組與C組比較差異無統計學意義(P>0.05 . B、C組視覺模擬評分(VAS)明顯低于A組(P<0.05). A組T2 MAP、HR與T1、T3比較差異均有統計學意義(P<0.05);B和C組T1、T2、 HR與A組比較差異均有統計學意義(P<0.05);C組T2 SpO2:有所下降,但與A組和B組比較差異無統計學意義(P>0.05);C組T2RR與T1、T3比較差異均有統計學意義(P<0.05).結論 舒芬太尼可以安全有效地用于甲狀腺手術中鎮靜和鎮痛,以0.2 μg/(kg·h）的負荷劑量持續輸註效果更佳.
목적 평개불동제량서분태니대갑상선수술환자적진정화진통효과.방법 택기행갑상선수술적60례환자수궤분위삼조:A、B、C조,매조각20례,분별우수술개시절피전10min완만정맥추주서분태니0.1、0.2、0.3μg/kg,연후이0.1ug/(kg·h)속도지속수주.기록삼조환자재수술절피시(T1)、술중견랍갑상선시(T2)급봉피시(T3)적평균동맥압(MAP)、심솔(HR)、맥박혈양포화도(SpO2)、호흡빈솔(RR)、진정평분화진통평분,병진행비교.결과 B、C조T1、T2 Ramsay분급체Ⅳ급적례수(B조13、14례,C조14、15례)명현다우A조(7、10례)(P<0.05).단B조여C조비교차이무통계학의의(P>0.05 . B、C조시각모의평분(VAS)명현저우A조(P<0.05). A조T2 MAP、HR여T1、T3비교차이균유통계학의의(P<0.05);B화C조T1、T2、 HR여A조비교차이균유통계학의의(P<0.05);C조T2 SpO2:유소하강,단여A조화B조비교차이무통계학의의(P>0.05);C조T2RR여T1、T3비교차이균유통계학의의(P<0.05).결론 서분태니가이안전유효지용우갑상선수술중진정화진통,이0.2 μg/(kg·h）적부하제량지속수주효과경가.
Objective To investigate the effects of sufentanil with different concentrations in patients control the sedative and analgesic in thyroid surgery. Methods Sixty patients with thyroid surgery were randomly equally divided into three groups before thyroidectomy: group A, group B and group C were respectively given 0.1, 0.2 and 0.3 μg/kg sufentanil by intravenous injection. At the infusion, 0.1 μg/(kg·h)
sufentanil was administered. The mean arterial pressure (MAP), heart rate (HR), the pulse of oxygen saturation (SpO2), respiratory rate (RR), the sedation score and visual analogue scales (VAS) at the time of incision (T1), upside pulling thyroid (T2) and seam skin (T3) were recorded. Results At T1 and T2,Ramsay Ⅳ level in group B (13, 14 cases) and group C (14, 15 cases) were more than those in group A(7,10 cases)(P < 0.05), but there were no significant difference between group B and group C (P > 0.05). VAS in group B and group C was significantly lower than that in group A (P< 0.05). AtT2, the MAP and HR in group A compared with T1 and T3, there was significant difference (P< 0.05). At T1 and T2 the MAP and HR in group B and group C compared with group A, there was significant difference (P < 0.05). Conclusion Sufentanil can be safe and effective for thyroid surgery and sedation analgesia, with loading dose of 0.2 μg /kg, followed by 0.1 μg/(kg ·h) continuous infusion better effect.
